Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Long MSTR Daily Target ETF vs Novo Nordisk A/S — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $31.81, while Novo Nordisk A/S trades at $44.72 (market cap $200.69B). The key difference: Novo Nordisk A/S pays a 3.98% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| MSTU | NVO | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $573.00 | $63.98 |
52-Week Low | $14.60 | $35.29 |
Market Cap | — | $200.69B |
Enterprise Value | — | $215.49B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTU, a US stock, trades at $33.31, down 8.64% in the last 24 hours. Technical indicators show a bullish trend with strong moving averages, while oscillators are neutral. The company recently executed a 10:1 reverse stock split and declared a $0.29 dividend for H2-2026. Key support and resistance levels are at $30 and $36, respectively.
The outlook for MSTU is mixed; bullish technicals contrast with negative media sentiment highlighting significant past value erosion. Risks include high volatility and leveraged ETF decay. Investors should weigh technical strength against fundamental uncertainties and sentiment concerns before considering a position.
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
